The Problem You Are Facing
Every cross-functional decision in your pharma is taking longer than it should.
Not by a little. By weeks.
The pattern looks like this. A VP drafts a decision memo. The memo enters a cascade: commercial reviews it, medical adds clarifying questions, regulatory checks labeling implications, market access pulls payer impact, a regional GM weighs in on timeline, legal sweeps it for risk, the original VP responds, the memo re-routes for confirmation. By the time the decision is actually made, twenty-one days have passed. For some decision classes, particularly anything touching payer access or KOL engagement strategy, it is over thirty.
You already know this is happening. Your senior team complains about it. Your launches show it. Your competitive response speed shows it. And every time someone proposes a fix, the proposed fix is a better meeting cadence or a new Slack channel, and nothing changes.
The reason nothing changes is that the problem is not communication. The problem is preparation.
Why It Keeps Happening
The cascade is structural. Each function genuinely needs to weigh in. You cannot flatten it without breaking the regulatory and operational logic of how pharma actually runs.
But each function's input requires thirty to ninety minutes of original synthesis work before that function can contribute. Reading the memo. Pulling the relevant data from the function's systems. Cross-checking against active campaigns, ongoing trials, payer formularies, MLR libraries, prescribing data. Writing a position. Returning it to the cascade.
That synthesis happens on each function's schedule. Cascade time is the sum of all the synthesis windows.
Twenty-one days is not a culture problem. It is the arithmetic of how the work is structured.
McKinsey has measured the broader pattern. Executives spend almost forty percent of their time making decisions, sixty percent of that time is poorly used, and forty percent of the people involved in any given decision add no value. Forty percent of new drug launches are delayed by commercial-medical misalignment. Up to thirty percent of pharma IT budgets are consumed by duplicated investments because functions cannot coordinate.
Your pharma is not unusually slow. Your pharma is normal. Normal is the problem.
The Solution
I build and deploy Human in the Loop, an AI agent layer purpose-built for the pharma cross-functional cascade.
Here is what it does inside your organization.
Every employee inside the cascade gets a personal AI agent. The agent has secure read access to the systems that employee already uses: CRM, clinical trial data, prescribing data, competitor intelligence, publications, payer formularies, MLR libraries, internal knowledge bases. The agent is calibrated to that employee's function, their decision authority, and their typical decision patterns.
When a cross-functional decision enters the cascade, three things happen in parallel:
- The routing layer identifies every function whose input is required for this decision class.
- Each agent generates a function-specific briefing for its human: what the decision is, what context matters, what prior steps produced, what this function is being asked to evaluate, and what the agent's recommended position is, with full reasoning and sources.
- Each briefing routes to the relevant human in their inbox, already decision-ready.
The human reviews. The synthesis work is already done. The human approves, edits, or overrides. The decision moves on, often in minutes.
The cascade is preserved. Decision authority is preserved. The audit trail is preserved and stronger than what you have today. What gets removed is the synthesis bottleneck that was actually consuming the twenty-one days.
The decision-maker at the top of the cascade does not chase status updates. They see a continuously updating dossier that aggregates function-level inputs as they land. When every required input is in, they see a single decision-ready brief with the full reasoning chain underneath. They approve, edit, or send back for clarification.
Why This Will Work for Your Organization
Three reasons.
First, this architecture is built around the boundary the regulators have drawn. The agent prepares. The human decides. Every decision retains a named human owner, a documented approval, and a full audit trail. The architecture is compliant with the Caremark duty, the EU AI Act, the FDA-EMA joint AI principles, and your internal SOPs. This is not a workaround. It is a deployment pattern that survives inspection.
Second, the architecture matches the actual shape of your operating model rather than fighting it. The reason generic enterprise productivity tools fail in pharma is that they assume the cascade is the problem. The cascade is not the problem. The synthesis work inside each step is the problem. Human in the Loop removes the synthesis bottleneck without dismantling the operating model that your medical, regulatory, and commercial functions need to keep running.
Third, the system gets sharper over time. Approval rate, override rate, and agent confidence are tracked per agent, per function, per decision class. When override rate climbs above a threshold, the agent flags for retraining or for tighter human oversight. When approval rate stabilizes high, the agent reallocates its preparation depth to higher-leverage tasks. The deployment improves under supervision rather than degrading.
What You Get
The deployment is structured as a sixty-to-ninety-day pilot, followed by phased rollout.
In the pilot, you get:
- An AI agent layer deployed across one or two priority decision classes (typical starting points: KOL engagement planning, payer access strategy, brand launch coordination)
- Function-specific agent calibration for medical, commercial, regulatory, market access, and field force roles inside scope
- Full audit trail and governance dashboard from day one, designed for inspection-readiness
- Documented human oversight architecture, override tracking, and continuous learning controls
- Measured baseline-to-pilot comparison on decision velocity, synthesis time per stakeholder, and approval rate
In phased rollout, the agent layer extends across additional decision classes, additional functions, and additional markets. Expected envelope of performance, based on the architectural targets and pilot benchmarks the system was designed against:
- Cross-functional decision time compressed to under one hour on median for routine decision classes
- KOL engagement preparation compressed to under ten minutes per engagement
- Adverse event triage and routing compressed to under three minutes with full audit trail
- Agent approval rate stabilizing above seventy percent by month three
- Override rate dropping below twenty-five percent by month twelve
- Productivity gain in the range of two million dollars annualized per one-hundred-person team in the deployment scope
These are the targets the architecture is designed to hit. Pilot scope, data hygiene, and operating model readiness affect the exact numbers in your specific case. That is what the pilot measures.
How to Start
The next step is a thirty-minute teardown call.
The output of that call is a one-page assessment specific to your organization. It identifies which decision classes inside your cascade are leaking the most time, which functions are most affected, which deployment pattern would fit your operating model, and what a sixty-to-ninety-day pilot would look like.
You do not need a procurement process to take the call. You do not need a data inventory done. You do not need to have a position on AI strategy. You need to spend thirty minutes describing how cross-functional decisions actually move through your organization. I do the rest.
If your pharma is over five hundred people and any cross-functional decision class is taking more than ten days, this is worth the call.
Book a 30-minute Human in the Loop teardown →
The pharma companies that fix this in the next twelve months will run a different shape of organization for the rest of the decade. The ones that do not will keep losing weeks to a cascade that was never designed to be fast.
